Efficient attenuation of NK cell-mediated liver injury through genetically manipulating multiple immunogenes by using a liver-directed vector

Journal of Immunology

Volumn 190, Issue 9, 2013, Pages 4821-4829

  Geng, Jianlin ^a,b   Wang, Xuefu ^a,b   Wei, Haiming ^a,b   Sun, Rui ^a,b   Tian, Zhigang ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ENHANCED GREEN FLUORESCENT PROTEIN; FRACTALKINE; GAMMA INTERFERON; INTERLEUKIN 10; PLASMID VECTOR; RANTES; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEPATITIS; ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CCL5 GENE; CONTROLLED STUDY; DOWN REGULATION; FRACTALKINE GENE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC MANIPULATION; IMMUNOREGULATION; IN VIVO STUDY; INTERLEUKIN 10 GENE; LIVER CELL; LIVER PROTECTION; LYMPHOCYTE FUNCTION; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; VIRAL GENE THERAPY;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; CELL LINE, TUMOR; CHEMOKINE CCL5; CHEMOKINE CX3CL1; GENETIC THERAPY; GENETIC VECTORS; HEPATOCYTES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; KILLER CELLS, NATURAL; LIVER; LIVER DISEASES; MICE; MICE, INBRED C57BL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876801661     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203129     Document Type: Article

References (28)

1. Gao, B., W. I. Jeong, and Z. Tian. 2008. Liver: An organ with predominant innate immunity. Hepatology 47: 729-736. (Pubitemid 351280741)
2. Suda, T., K. Kamimura, T. Kubota, Y. Tamura, M. Igarashi, H. Kawai, Y. Aoyagi, and D. Liu. 2009. Progress toward liver-based gene therapy. Hepatol. Res. 39: 325-340.
3. Nguyen, T. H., and N. Ferry. 2004. Liver gene therapy: advances and hurdles. Gene Ther. 11(Suppl 1): S76-S84. (Pubitemid 39359451)
4. Marshall, E. 1999. Gene therapy death prompts review of adenovirus vector. Science 286: 2244-2245. (Pubitemid 30016842)
5. Morral, N., W. O'Neal, K. Rice, M. Leland, J. Kaplan, P. A. Piedra, H. Zhou, R. J. Parks, R. Velji, E. Aguilar-Córdova, et al. 1999. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA 96: 12816-12821. (Pubitemid 29513585)
6. Wang, L., R. Hernández-Alcoceba, V. Shankar, M. Zabala, S. Kochanek, B. Sangro, M. G. Kramer, J. Prieto, and C. Qian. 2004. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology 126: 278-289. (Pubitemid 38040742)
7. Mok, H., D. J. Palmer, P. Ng, and M. A. Barry. 2005. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11: 66-79. (Pubitemid 40012000)
8. Zhu, J., X. Huang, and Y. Yang. 2010. NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. J. Immunol. 185: 7480-7486.
9. Chen, Q., H. Wei, R. Sun, J. Zhang, and Z. Tian. 2008. Therapeutic RNA silencing of Cys-X3-Cys chemokine ligand 1 gene prevents mice from adenovirus vector-induced acute liver injury. Hepatology 47: 648-658. (Pubitemid 351280733)
10. Zhu, J., X. Huang, and Y. Yang. 2008. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol. Ther. 16: 1300-1307. (Pubitemid 351866062)
11. Oberholzer, C., A. Oberholzer, S. K. Tschoeke, R. M. Minter, F. R. Bahjat, D. LaFace, B. Hutchins, and L. L. Moldawer. 2004. Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression. J. Endotoxin Res. 10: 393-401. (Pubitemid 39618554)
12. Pastore, L., N. Morral, H. Zhou, R. Garcia, R. J. Parks, S. Kochanek, F. L. Graham, B. Lee, and A. L. Beaudet. 1999. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum. Gene Ther. 10: 1773-1781. (Pubitemid 29357683)
13. Nathwani, A. C., J. T. Gray, C. Y. Ng, J. Zhou, Y. Spence, S. N. Waddington, E. G. Tuddenham, G. Kemball-Cook, J. McIntosh, M. Boon-Spijker, et al. 2006. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduc-tion of murine and nonhuman primate liver. Blood 107: 2653-2661.
14. Kramer, M. G., M. Barajas, N. Razquin, P. Berraondo, M. Rodrigo, C. Wu, C. Qian, P. Fortes, and J. Prieto. 2003. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol. Ther. 7: 375-385. (Pubitemid 36503861)
15. Blum, H. E. 2007. Molecular therapy and prevention of liver diseases. Adv. Med. Sci. 52: 29-36.
16. Chen, Q., W. Lou, J. Shen, L. Ma, Z. Yang, L. Liu, J. Luo, and C. Qian. 2010. Potent antitumor activity in experimental hepatocellular carcinoma by adenovirus-mediated coexpression of TRAIL and shRNA against COX-2. Clin. Cancer Res. 16: 3696-3705.
17. Liu, F., Y. Song, and D. Liu. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6: 1258-1266. (Pubitemid 29359019)
18. Sun, R., Z. Tian, S. Kulkarni, and B. Gao. 2004. IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell-and STAT3-dependent manners. J. Immunol. 172: 5648-5655. (Pubitemid 38542068)
19. Witting, S. R., M. Brown, R. Saxena, S. Nabinger, and N. Morral. 2008. Helper-dependent adenovirus-mediated short hairpin RNA expression in the liver activates the interferon response. J. Biol. Chem. 283: 2120-2128.
20. Liu, Q., A. K. Zaiss, P. Colarusso, K. Patel, G. Haljan, T. J. Wickham, and D. A. Muruve. 2003. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum. Gene Ther. 14: 627-643. (Pubitemid 36543435)
21. Raper, S. E., N. Chirmule, F. S. Lee, N. A. Wivel, A. Bagg, G. P. Gao, J. M. Wilson, and M. L. Batshaw. 2003. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80: 148-158. (Pubitemid 37272241)
22. Worgall, S., G. Wolff, E. Falck-Pedersen, and R. G. Crystal. 1997. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8: 37-44. (Pubitemid 27075341)
23. Jooss, K., H. C. Ertl, and J. M. Wilson. 1998. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J. Virol. 72: 2945-2954. (Pubitemid 28175532)
24. Muruve, D. A., M. J. Barnes, I. E. Stillman, and T. A. Libermann. 1999. Ade-noviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10: 965-976. (Pubitemid 29195426)
25. Ouyang, W., S. Rutz, N. K. Crellin, P. A. Valdez, and S. G. Hymowitz. 2011. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29: 71-109.
26. Gaddi, P. J., M. J. Crane, M. Kamanaka, R. A. Flavell, G. S. Yap, and T. P. Salazar-Mather. 2012. IL-10 mediated regulation of liver inflammation during acute murine cytomegalovirus infection. PLoS ONE 7: e42850.
27. Silva, J. M., M. Z. Li, K. Chang, W. Ge, M. C. Golding, R. J. Rickles, D. Siolas, G. Hu, P. J. Paddison, M. R. Schlabach, et al. 2005. Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 37: 1281-1288. (Pubitemid 41568714)
28. Giering, J. C., D. Grimm, T. A. Storm, and M. A. Kay. 2008. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol. Ther. 16: 1630-1636.